Deal With Arcellx Gives Gilead New Beachhead In Multiple Myeloma

 
• By Alaric DeArment

Deal Snapshot: Months after terminating its Phase I BCMA-targeting CAR-T program and on the eve of ASH, Gilead’s Kite announced a deal with Arcellx for a CAR-T that has already shown promising data.

Gilead and Arcellx announced a development and commercialization partnership for CART-ddBCMA • Source: Shutterstock

More from Deals

More from Business